The findings show that NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection) can be used effectively once and up to three times daily among patients who were unsuccessfully treated with oral antidiabetic agents (OADs) with or without basal insulin therapy.
Data from the ‘1-2-3 Study’ presented at the 65th annual Scientific Sessions of the American Diabetes Association (ADA), show that 41% of the patients enrolled in the trial achieved the ADA A1C target of less than or equal to 7%, and 21% achieved an A1C level less than or equal to 6.5% when receiving just a single daily dose of NovoLog Mix 70/30.
Furthermore, 77% achieved the 7% target through receiving up to three doses per day. Sixty percent achieved the 6.5% level on the same basis.
“These results are particularly encouraging for patients who are inadequately treated with OADs,” said Dr Garber, lead investigator and Professor of Medicine Biochemistry and Cell Biology at Baylor College of Medicine.
“Now physicians can feel comfortable in prescribing a once-daily dose of NovoLog Mix 70/30 to control diabetes. For those patients not controlled with a single dose, our study clearly demonstrates how a physician can then easily transition patients to two doses and occasionally, as necessary, three doses a day of the same insulin to achieve target A1C goals.”